Literature DB >> 26399621

Management of Suspected Choledocholithiasis: A Decision Analysis for Choosing the Optimal Imaging Modality.

Amnon Sonnenberg1,2, Brintha K Enestvedt3, Gennadiy Bakis3.   

Abstract

BACKGROUND AND AIMS: Magnetic resonance cholangiography (MRC), endoscopic ultrasound (EUS), and endoscopic retrograde cholangio-pancreatography (ERCP) all represent viable options to establish the diagnosis of choledocholithiasis. The aim of the study was to assess how the three imaging modalities perform in head-to-head comparisons and in what order to apply them when using these procedures sequentially.
METHODS: A threshold analysis using a decision tree was modeled to compare the costs associated with different imaging techniques of the biliary system in a patient with suspected cholestasis secondary to choledocholithiasis. The main outcome parameter was the pre-test probability of common bile duct (CBD) stones that would guide the physician towards starting the work-up with MRC or EUS versus going straight to ERCP as the primary procedure.
RESULTS: For low pre-test probabilities of CBD stones in the common bile duct, MRC represents the procedure of choice. For pre-test probabilities ranging between 40 and 91 %, EUS should be the preferred imaging modality. If CBD stones are suspected with an even higher pre-test probability, patients could go straight to ERCP as their first procedure. Low costs associated with any of the three procedures increase its range of applicability at the expense of the other competing imaging modalities.
CONCLUSIONS: MRC, EUS, and ERCP should be used in sequence and dependent on the pre-test probability of choledocholithiasis.

Entities:  

Keywords:  Biliary imaging; Cholestasis; Decision analysis; Endoscopic retrograde cholangio-pancreatography (ERCP); Endoscopic ultrasound (EUS); Magnetic resonance cholangiography (MRC); Threshold analysis

Mesh:

Year:  2015        PMID: 26399621     DOI: 10.1007/s10620-015-3882-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  14 in total

1.  Cost-effective management of common bile duct stones: a decision analysis of the use of endoscopic retrograde cholangiopancreatography (ERCP), intraoperative cholangiography, and laparoscopic bile duct exploration.

Authors:  D R Urbach; Y S Khajanchee; B A Jobe; B A Standage; P D Hansen; L L Swanstrom
Journal:  Surg Endosc       Date:  2001-01       Impact factor: 4.584

2.  The role of endoscopy in the evaluation of suspected choledocholithiasis.

Authors:  John T Maple; Tamir Ben-Menachem; Michelle A Anderson; Vasundhara Appalaneni; Subhas Banerjee; Brooks D Cash; Laurel Fisher; M Edwyn Harrison; Robert D Fanelli; Norio Fukami; Steven O Ikenberry; Rajeev Jain; Khalid Khan; Mary Lee Krinsky; Laura Strohmeyer; Jason A Dominitz
Journal:  Gastrointest Endosc       Date:  2010-01       Impact factor: 9.427

3.  MRCP is not a cost-effective strategy in the management of silent common bile duct stones.

Authors:  Irene Epelboym; Megan Winner; John D Allendorf
Journal:  J Gastrointest Surg       Date:  2013-03-21       Impact factor: 3.452

4.  Cost-effective treatment of patients with symptomatic cholelithiasis and possible common bile duct stones.

Authors:  Lisa M Brown; Stanley J Rogers; John P Cello; Karen J Brasel; John M Inadomi
Journal:  J Am Coll Surg       Date:  2011-03-27       Impact factor: 6.113

5.  The threshold approach to clinical decision making.

Authors:  S G Pauker; J P Kassirer
Journal:  N Engl J Med       Date:  1980-05-15       Impact factor: 91.245

6.  Can endoscopic ultrasound or magnetic resonance cholangiopancreatography replace ERCP in patients with suspected biliary disease? A prospective trial and cost analysis.

Authors:  J M Scheiman; R C Carlos; J L Barnett; G H Elta; T T Nostrant; W D Chey; I R Francis; P S Nandi
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

7.  Nonoperative imaging techniques in suspected biliary tract obstruction.

Authors:  Frances Tse; Jeffrey S Barkun; Joseph Romagnuolo; Gad Friedman; Jeffrey D Bornstein; Alan N Barkun
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

8.  Cost-effectiveness of endoscopic ultrasonography, magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography in patients suspected of pancreaticobiliary disease.

Authors:  A P Ainsworth; S R Rafaelsen; P A Wamberg; T Pless; J Durup; M B Mortensen
Journal:  Scand J Gastroenterol       Date:  2004-06       Impact factor: 2.423

9.  EUS: a meta-analysis of test performance in suspected choledocholithiasis.

Authors:  Frances Tse; Louis Liu; Alan N Barkun; David Armstrong; Paul Moayyedi
Journal:  Gastrointest Endosc       Date:  2008-02       Impact factor: 9.427

Review 10.  A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography.

Authors:  E Kaltenthaler; Y Bravo Vergel; J Chilcott; S Thomas; T Blakeborough; S J Walters; H Bouchier
Journal:  Health Technol Assess       Date:  2004-03       Impact factor: 4.014

View more
  3 in total

1.  Impacts on outcomes and management of preoperative magnetic resonance cholangiopancreatography in patients scheduled for laparoscopic cholecystectomy: for whom it should be considered?

Authors:  Kyung A Kang; Heon-Ju Kwon; Soo-Youn Ham; Hee Jin Park; Jun Ho Shin; Sung Ryol Lee; Mi Sung Kim
Journal:  Ann Surg Treat Res       Date:  2020-09-24       Impact factor: 1.859

Review 2.  EUS and ERCP: A rationale categorization of a productive partnership.

Authors:  Juan J Vila; Iñaki Fernández-Urién; Juan Carrascosa
Journal:  Endosc Ultrasound       Date:  2021 Jan-Feb       Impact factor: 5.628

3.  The Diagnostic Value of GGT-Based Biochemical Indicators for Choledocholithiasis with Negative Imaging Results of Magnetic Resonance Cholangiopancreatography.

Authors:  Huajun Lin; Xiaona Zhou; Zhongtao Zhang
Journal:  Contrast Media Mol Imaging       Date:  2022-06-27       Impact factor: 3.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.